Targeted Therapies in Small Cell Lung Cancer: From Old Failures to Novel Therapeutic Strategies

The clinical management of small cell lung cancer (SCLC) treatment remains a major challenge for thoracic oncologists, with very few therapeutic advances significantly impacting patients’ survival. The recent introduction of immunotherapy in the clinical setting produced a marginal benefit for a limited subset of metastatic patients, while the therapeutic scenario for relapsing extended-disease small cell lung cancers (ED-SCLCs) remains almost deserted. Recent efforts clarified the molecular features of this disease, leading to the identification of key signalling pathways which may serve as potential targets for clinical use. Despite the large number of molecules tested and the numerous therapeutic failures, some targeted therapies have recently shown interesting preliminary results. In this review, we describe the main molecular pathways involved in SCLC development/progression and provide an updated summary of the targeted therapies currently under investigation in SCLC patients.

[1]  S. Domchek,et al.  Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1/2, basket study. , 2023, Lung cancer.

[2]  L. Ellis,et al.  Polycomb Directed Cell Fate Decisions in Development and Cancer , 2022, Epigenomes.

[3]  C. Rudin,et al.  WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC , 2022, Cell reports.

[4]  J. Kashima,et al.  Advances in biology and novel treatments of SCLC: The four-color problem in uncharted territory. , 2022, Seminars in cancer biology.

[5]  A. Nicholson,et al.  The 2021 WHO Classification of Lung Tumors: Impact of advances since 2015. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  Y. Liu,et al.  Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study , 2021, British Journal of Cancer.

[7]  Melissa L. Johnson,et al.  A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer. , 2021, Clinical lung cancer.

[8]  C. Rudin,et al.  Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  S. Steinberg,et al.  Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress. , 2021, Cancer cell.

[10]  Tengyu Ma,et al.  MA13.03 DNA Damage Response Gene Alterations and their Association with Tumor Mutation Burden and Response to Immunotherapy in NSCLC and SCLC , 2021 .

[11]  K. Nackaerts,et al.  Efficacy and Safety of Rovalpituzumab Tesirine Compared with Topotecan as Second-Line Therapy in DLL3-High Small Cell Lung Cancer: Results from the Phase 3 TAHOE Study. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  S. Gettinger,et al.  Second-Line Nivolumab in Relapsed Small-Cell Lung Cancer: CheckMate 331. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  C. Rudin,et al.  Small-cell lung cancer , 2021, Nature Reviews Disease Primers.

[14]  N. Reinmuth,et al.  Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133) , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  P. Robson,et al.  Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. , 2021, Cancer cell.

[16]  S. Batra,et al.  Epigenetic Landscape of Small Cell Lung Cancer: Small Image of a Giant Recalcitrant Disease. , 2020, Seminars in cancer biology.

[17]  X. Hou,et al.  Comparison of First-Line Treatments for Patients With Extensive-Stage Small Cell Lung Cancer , 2020, JAMA network open.

[18]  Y. Bang,et al.  Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. , 2020, The Lancet. Oncology.

[19]  C. Chouaid,et al.  Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial. , 2020, The Lancet. Oncology.

[20]  P. Meltzer,et al.  Epigenome-wide DNA methylation analysis of small cell lung cancer cell lines suggests potential chemotherapy targets , 2020, Clinical Epigenetics.

[21]  P. Ascierto,et al.  Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[22]  K. Nackaerts,et al.  Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for Small-Cell Lung Cancer: Primary and Correlative Biomarker Analyses. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[23]  D. Planchard,et al.  Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic Small-Cell Lung Cancer: Results From the KEYNOTE-028 and KEYNOTE-158 Studies. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[24]  Young Hak Kim,et al.  Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial , 2019, The Lancet.

[25]  Wenfeng Li,et al.  Apatinib in patients with extensive-stage small-cell lung cancer after second-line or third-line chemotherapy: a phase II, single-arm, multicentre, prospective study , 2019, British Journal of Cancer.

[26]  C. Rudin,et al.  Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study , 2019, Clinical Cancer Research.

[27]  M. Lawrence,et al.  Combination Olaparib and Temozolomide in Relapsed Small Cell Lung Cancer. , 2019, Cancer discovery.

[28]  S. Steinberg,et al.  Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[29]  C. Rudin,et al.  Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data , 2019, Nature Reviews Cancer.

[30]  Carlos F. Lopez,et al.  Systems-level network modeling of Small Cell Lung Cancer subtypes identifies master regulators and destabilizers , 2019, PLoS Comput. Biol..

[31]  G. Sica,et al.  Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  E. Lobenhofer,et al.  P3.12-03 Targeting DLL3 with AMG 757, a BiTE® Antibody Construct, and AMG 119, a CAR-T, for the Treatment of SCLC , 2018, Journal of Thoracic Oncology.

[33]  C. Rudin,et al.  Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  O. Abdel-Rahman.  Changing epidemiology of elderly small cell lung cancer patients over the last 40 years; a SEER database analysis , 2018, The clinical respiratory journal.

[35]  Pan Tong,et al.  CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib. , 2017, Cancer research.

[36]  V. Moreno,et al.  Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  J. Li,et al.  Survival changes in patients with small cell lung cancer and disparities between different sexes, socioeconomic statuses and ages , 2017, Scientific Reports.

[38]  C. Rudin,et al.  Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis. , 2017, Cancer cell.

[39]  C. Galmarini,et al.  Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer Cells , 2016, Molecular Cancer Therapeutics.

[40]  C. la Vecchia,et al.  Screening with Low‐Dose Computed Tomography Does Not Improve Survival of Small Cell Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[41]  C. Rudin,et al.  A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo , 2015, Science Translational Medicine.

[42]  Martin Vingron,et al.  Comprehensive genomic profiles of small cell lung cancer , 2015, Nature.

[43]  John T. Poirier,et al.  DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2 , 2015 .

[44]  Yuanhua Liu,et al.  Knocking down the expression of Aurora-A gene inhibits cell proliferation and induces G2/M phase arrest in human small cell lung cancer cells. , 2014, Oncology reports.

[45]  M. Ladanyi,et al.  Small-Cell Lung Cancers in Patients Who Never Smoked Cigarettes , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[46]  B. Halmos,et al.  Phase II trial of Sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer , 2014, Investigational New Drugs.

[47]  C. Gatsonis,et al.  Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .

[48]  M. Socinski,et al.  Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  J. Jett,et al.  Characteristics and Outcomes of Small Cell Lung Cancer Patients Diagnosed During Two Lung Cancer Computed Tomographic Screening Programs in Heavy Smokers , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[50]  Cary A Moody,et al.  Human papillomavirus oncoproteins: pathways to transformation , 2010, Nature Reviews Cancer.

[51]  A. Hackshaw,et al.  Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. , 2009, Journal of the National Cancer Institute.

[52]  J. Hainsworth,et al.  Phase II Trial of Irinotecan, Carboplatin, and Bevacizumab in the Treatment of Patients with Extensive-Stage Small-Cell Lung Cancer , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[53]  H. Lane,et al.  AKT/mTOR Pathway Activation and BCL-2 Family Proteins Modulate the Sensitivity of Human Small Cell Lung Cancer Cells to RAD001 , 2009, Clinical Cancer Research.

[54]  John Calvin Reed,et al.  Bcl-2 family proteins and cancer , 2008, Oncogene.

[55]  A. Rossi,et al.  New targeted therapies and small-cell lung cancer. , 2008, Clinical lung cancer.

[56]  D. N. Watkins,et al.  Cancer stem cells and the ontogeny of lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  F. Berthold,et al.  Targeting the neural cell adhesion molecule in cancer. , 2007, Cancer letters.

[58]  A. Arcaro,et al.  Targeting receptor tyrosine kinase signalling in small cell lung cancer (SCLC): what have we learned so far? , 2007, Cancer treatment reviews.

[59]  J. Minna,et al.  A Translational View of the Molecular Pathogenesis of Lung Cancer , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[60]  R. Salgia,et al.  Targeted molecules in small cell lung cancer. , 2004, Seminars in oncology.

[61]  Michael F. Clarke,et al.  Applying the principles of stem-cell biology to cancer , 2003, Nature Reviews Cancer.

[62]  S. Baylin,et al.  Hedgehog Signaling: Progenitor Phenotype in Small-Cell Lung Cancer , 2003, Cell cycle.

[63]  R. Salgia,et al.  Molecular and cellular biology of small cell lung cancer. , 2003, Seminars in oncology.

[64]  H. Joensuu,et al.  High pretreatment serum concentration of basic fibroblast growth factor is a predictor of poor prognosis in small cell lung cancer. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[65]  J. Litz,et al.  Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy. , 2002, Molecular cancer therapeutics.

[66]  I. Gout,et al.  Novel cross talk between MEK and S6K2 in FGF-2 induced proliferation of SCLC cells , 2001, Oncogene.

[67]  O. Bogler,et al.  Notch signaling inhibits muscle cell differentiation through a CBF1-independent pathway. , 1996, Development.

[68]  A. Gazdar,et al.  Telomerase activity in small-cell and non-small-cell lung cancers. , 1995, Journal of the National Cancer Institute.

[69]  J. Minna,et al.  Molecular genetics of lung cancer. , 2003, Seminars in oncology.

[70]  C. Croce,et al.  Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. , 1982, Proceedings of the National Academy of Sciences of the United States of America.